Evidence map›Paper›PMID 32024773›Full record

ArticleJournal of virology2020

A Novel Immunogen Selectively Eliciting CD8

Hiroshi Ishii, Kazutaka Terahara, Takushi Nomura, Akiko Takeda, Midori Okazaki, Hiroyuki Yamamoto, Tsuyoshi Tokusumi, Tsugumine Shu, Tetsuro Matano

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hiroshi IshiiAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Kazutaka TeraharaDepartment of Immunology, National Institute of Infectious Diseases, Tokyo, Japan.
Takushi NomuraAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Akiko TakedaAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Midori OkazakiAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Hiroyuki YamamotoAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Tsuyoshi TokusumiID Pharma Co., Ltd., Ibaraki, Japan.
Tsugumine ShuID Pharma Co., Ltd., Ibaraki, Japan.
Tetsuro MatanoAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan tmatano@nih.go.jp.
National Institute of Infectious Diseases · JPID Pharma (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimization of immunogen is crucial for induction of effective T-cell responses in the development of a human immunodeficiency virus (HIV) vaccine. Conventional T-cell-based vaccines have been designed to induce virus-specific CD4

Indexed as

AIDS VaccinesAmino Acid SequenceAnimalsAntigens, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDisease Models, Animalgag Gene Products, Human Immunodeficiency VirusHIV InfectionsImmunizationMacaca mulattaSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVaccinationvif Gene Products, Human Immunodeficiency VirusViral LoadAIDS VaccinesAntigens, Viralgag Gene Products, Human Immunodeficiency Virusvif Gene Products, Human Immunodeficiency VirusCD4HIVSIVT cellvaccine

Identifiers

PMID32024773
PMCPMC7108830
OpenAlexW3003391096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.